Validation of the Newly Developed North America Islet Donor Scoring System in the Medium Volume Islet Transplant Center.
1Surgery, University of Chicago, Chicago, IL
2Surgery, Medical University of Gdansk, Gdansk, Poland
3Internal Medicine, Medical University of Gdansk, Gdansk, Poland
4Surgery, University of Illinois, Chicago, IL
5Surgery, University of Alberta, Edmonton, AB, Canada
6Medicine, University of Chicago, Chicago, IL.
Meeting: 2016 American Transplant Congress
Abstract number: B99
Session Information
Session Name: Poster Session B: Donor Management: All Organs
Session Type: Poster Session
Date: Sunday, June 12, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background.
North America Islet Donor Scoring (NAIDS) system has been recently developed for selection of the optimal pancreas donor based on analysis of the results from 1089 islet isolations in eleven centers. NAIDS ranges 0-100points; the higher score, the higher chance for successful islet isolation. NAIDS was found to have better discriminative ability for the success of the isolation then previously developed scoring in Edmonton. The goal was to validate NAIDS in our, medium volume islet transplant program.
Methods.
We analyzed pancreas donor results of 70 islet isolations performed in our center since 2009. NAIDS was calculated based on donor body weight, BMI, body surface area, lab tests (serum amylase, Na, glucose, ALT, AST, BUN, HbA1c), use of vasopressors, procuring team and cold ischemia time. Post-purification islet yield over 400,000 islet equivalents was used as threshold for successful islet isolation. Comparable data from the multicenter study was used for NAIDS validation.
Results.
Receiver Operating Characteristic (ROC) curve was plotted using our validation cohort data. ROC–area under the curve (AUC) was 0.659 [95% confidence interval 0.526-0.793], which was not significantly different (P=0.31) from that obtained from the NAIDS development cohort 0.730 [95% confidence interval 0.697-0.763]. A similar proportional increase in the success rate was observed in our as well as in the multicenter study as the score is increasing: 6.3% and 12% for NAISD <60; 25% and 26% for NAIDS =60-70; 27% and 36% for NAIDS =70-80; 44% and 54% for NAIDS >80, respectively.
Conclusion.
We validated newly developed NAIDS system in our, medium volume islet transplant program. NAIDS is an important tool to guide pancreas donor selection and adjust it to islet program development strategy, resources and funding.
CITATION INFORMATION: Solomina J, Matosz S, Sledzinski M, Golebiewska J, Savaril O, Wang L.-J, Kin T, Golab K, Ramachandran S, Tibudan M, Schenck L, Chon W, Thomas C, Witkowski P. Validation of the Newly Developed North America Islet Donor Scoring System in the Medium Volume Islet Transplant Center. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Solomina J, Matosz S, Sledzinski M, Golebiewska J, Savaril O, Wang L-J, Kin T, Golab K, Ramachandran S, Tibudan M, Schenck L, Chon W, Thomas C, Witkowski P. Validation of the Newly Developed North America Islet Donor Scoring System in the Medium Volume Islet Transplant Center. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/validation-of-the-newly-developed-north-america-islet-donor-scoring-system-in-the-medium-volume-islet-transplant-center/. Accessed May 21, 2025.« Back to 2016 American Transplant Congress